ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.51
-0.01 (-2.13%)
At close: 4:00PM EDT

0.52 +0.01 (1.96%)
After hours: 4:28PM EDT

Stock chart is not supported by your current browser
Previous Close0.52
Open0.52
Bid0.52 x 800
Ask0.54 x 800
Day's Range0.51 - 0.55
52 Week Range0.45 - 2.00
Volume528,669
Avg. Volume876,485
Market Cap7.101M
Beta3.83
PE Ratio (TTM)N/A
EPS (TTM)-1.06
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.10
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA).  The request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for heart failure (HF) patients at risk for atrial fibrillation (AF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.

  • GlobeNewswirelast month

    ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    WESTMINSTER, Colo., Aug. 09, 2018-- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...

  • ACCESSWIRE2 months ago

    Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018

    Last month, for instance, GT Biopharma (GTBP) announced a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. This Major Pharmaceutical Company will be supplying a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • ACCESSWIRE2 months ago

    3 Biotech Stocks in Focus on Tuesday

    CORAL GABLES, FL / ACCESSWIRE / July 31, 2018 / The Nasdaq iShares Biotechnology Index (IBB) has taken a turn toward ''greener pastures.'' The ETF rose by more than 1.2% on Tuesday as a number of biotech stocks moved higher in early morning trading. GT Biopharma (GTBP) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms. Earlier this month the company announced the addition of Dr. John N. Bonfiglio to GT Biopharma's Board of Directors.

  • GlobeNewswire2 months ago

    ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 2 meeting regarding the Phase 3 program for ARCA’s pharmacologically unique beta-blocker Gencaro as a potential genetically-targeted treatment for atrial fibrillation (AF) patients with heart failure (HF). Based on review of the Phase 2 GENETIC-AF trial results, as well as its alignment with previous Phase 3 pharmacogenetic substudy data, the FDA stated that data from a single pivotal Phase 3 clinical trial may be sufficient to support approval of Gencaro for the treatment of AF in patients with HF.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after ...

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks

    Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...

  • ACCESSWIRE4 months ago

    Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE6 months ago

    Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

    Stock Monitor: ARCA biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on Insmed Inc. (NASDAQ: INSM ). If you want ...

  • SmarterAnalyst7 months ago

    Here’s Why Arca Biopharma Inc (ABIO) Shares Are Skyrocketing Today

    Case in point: Arca Biopharma Inc (NASDAQ:ABIO), whose shares are jumping 40% on Tuesday. Why? The drug maker announced positive results from its Phase 2B trial evaluating GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF). In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, metoprolol succinate (TOPROL-XL).

  • Market Exclusive7 months ago

    ARCA biopharma And ObsEva Just Put Out Clinical Trial Data

    ARCA biopharma, Inc. (NASDAQ:ABIO) has had a rough start to the week this week. The company put out a release detailing the progress of a phase II trial that was put in place to investigate an asset called Gencaro, which ARCA is trying to demonstrate can be a safe and effective treatment for atrial fibrillation […] The post ARCA biopharma And ObsEva Just Put Out Clinical Trial Data appeared first on Market Exclusive.

  • One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO)
    Simply Wall St.8 months ago

    One Thing To Consider Before Buying ARCA biopharma Inc (NASDAQ:ABIO)

    If you are a shareholder in ARCA biopharma Inc’s (NASDAQ:ABIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • What You Must Know About ARCA biopharma Inc’s (NASDAQ:ABIO) Major Investors
    Simply Wall St.9 months ago

    What You Must Know About ARCA biopharma Inc’s (NASDAQ:ABIO) Major Investors

    In this article, I’m going to take a look at ARCA biopharma Inc’s (NASDAQ:ABIO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • Interested In Healthcare? Why ARCA biopharma Inc (ABIO) May Be The Entry Point
    Simply Wall St.9 months ago

    Interested In Healthcare? Why ARCA biopharma Inc (ABIO) May Be The Entry Point

    ARCA biopharma Inc (NASDAQ:ABIO), a USD$14.69M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • How Much is ARCA biopharma Inc’s (ABIO) CEO Getting Paid?
    Simply Wall St.10 months ago

    How Much is ARCA biopharma Inc’s (ABIO) CEO Getting Paid?

    Michael Bristow took the helm as ARCA biopharma Inc’s (NASDAQ:ABIO) CEO and grew market cap to USD$14.69M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • ACCESSWIRE10 months ago

    ARCA Biopharma, European Patent for Gencaro and Q3 Review

    NEW YORK, NY / ACCESSWIRE / November 20, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Stocks to Watch: ARCA biopharma and Amicus Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Shares of ARCA biopharma saw big gains on Thursday after announcing a European Patent win that provides protection for a novel approach to treating patients ...